Skip to main content

Table 1 Patients demographics and clinical variables

From: Does pulmonary subspecialty referral from primary care affect the adherence to vaccination recommendations in COPD patients?

  No pulmonary clinic visit in prior 3 years (n = 122) Pulmonary clinic visit in prior 3 years (n = 78) p value
Age in years (mean ± SD) 70.5 ± 10.8 70.4 ± 10.9 0.9
Age ≥ 65-year-old, n(%) 82 (65.5) 54 (69.2) 0.7
Men, n (%) 56 (45.9) 44 (56.4) 0.2
Smoking status, n (%)
 Never 6 (4.9) 10 (12.8) 0.005
 Former 57 (46.7) 20 (25.6)
 Current 56 (45.9) 46 (58.9)
PFT ever done, n (%) 70 (57.3) 77 (98.7) < 0.001
Obstructive pattern confirmed on PFT (%) 42 (60.0) 66 (85.7) < 0.001
FEV1/FVC (mean ± SD) 69.4 ± 11.3 65.1 ± 14.6 0.07
Airflow limitation by FEV1 in those with obstructive pattern, n (%)
 GOLD 1 (mild) 8 (19.0) 7 (10.6) 0.02
 GOLD2 (moderate) 28 (66.6) 30 (45.5)
 GOLD 3 (severe) 5 (11.9) 24 (36.4)
 GOLD 4 (very severe) 1 (2.4) 5 (7.5)
PCV13, n (%) 71/87 (81.6) 57/59 (96.6) 0.009
PPSV23, n (%) 100/118 (84.7) 74/78 (94.8) 0.03
Influenza vaccination 2017, n (%) 77(63.1) 63(80.8) 0.008
Influenza vaccination 2018, n (%) 76(62.8) 62(80.5) 0.008
Influenza vaccination 2019, n (%) 60 (52.2) 53(70.7) 0.01
COPD hospitalization in prior 12 months, n (%) 3 (2.4) 16 (20.5) < 0.001
Death in 2017–2019, n (%) 8 (6.5) 5 (6.4) 1.0
  1. COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, PFT Pulmonary Function Testing, PCV13 pneumococcal conjugate vaccine, PPSV23 pneumococcal polysaccharide vaccine, SD standard deviation
\